Detalhe da pesquisa
1.
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(2): 242-249, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31838011
2.
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Gynecol Oncol
; 156(3): 629-635, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31926638
3.
[Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].
Gan To Kagaku Ryoho
; 37(7): 1307-11, 2010 Jul.
Artigo
em Japonês
| MEDLINE | ID: mdl-20647715
4.
[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].
Gan To Kagaku Ryoho
; 36(8): 1327-31, 2009 Aug.
Artigo
em Japonês
| MEDLINE | ID: mdl-19692772
5.
Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.
BMJ Open
; 9(1): e024357, 2019 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30782732